{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:40:16Z","timestamp":1777934416871,"version":"3.51.4"},"reference-count":40,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>Retinoblastoma is the most common paediatric ocular tumour, which appears in the retina. Without treatment, retinoblastoma grows and destroys the internal ocular globe architecture, even leading to metastasis. When treated, overall survival is close to 97%, the alkylating drug melphalan being the most extensively used chemotherapeutic agent in localised treatment. The aim of this study is to describe the implementation of a new intravitreal chemotherapy retinoblastoma treatment protocol for children implanting vitreous seeds through intravitreal melphalan injections and to evaluate the patients\u2019 health outcomes treated with it. Between December 2014 and July 2018, seven patients were treated with this protocol. They received a mean of 3.3 cycles of intravitreal melphalan with standard doses of 30\u2009mcg per cycle. In the seven eyes treated in our hospital, the response was as expected; three eyes with vitreous seedings (43%) were successfully treated. The main adverse effects presented by all patients were scars at cryogenisation points. In two patients, the appearance of \u2018salt and pepper\u2019 retinopathy was reported. Oncology pharmacists, as part of the treatment team, can provide information about recommended doses, expected adverse effects, stability of preparations, most appropriate method of processing, packaging, and methods of drug administration, to ensure efficacy and especially safety in the administration of these drugs.<\/jats:p>","DOI":"10.1177\/1078155220904410","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T03:58:36Z","timestamp":1581911916000},"page":"1829-1835","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8804-3878","authenticated-orcid":false,"given":"Antonio","family":"Solana-Altabella","sequence":"first","affiliation":[{"name":"H.U.P. La Fe, Pharmacy Department, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Valero","sequence":"additional","affiliation":[{"name":"H.U.P. La Fe, Pharmacy Department, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Balaguer","sequence":"additional","affiliation":[{"name":"H.U.P. La Fe, Paediatric Oncology Department, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paloma","family":"Escobar-Cava","sequence":"additional","affiliation":[{"name":"H.U.P. La Fe, Pharmacy Department, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honorio","family":"Barranco","sequence":"additional","affiliation":[{"name":"H.U.P. La Fe, Paediatric Ophthalmology Department, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"H.U.P. La Fe, Pharmacy Department, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Ribes-Artero","sequence":"additional","affiliation":[{"name":"H.U.P. La Fe, Pharmacy Department, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Poveda","sequence":"additional","affiliation":[{"name":"H.U.P. La Fe, Pharmacy Department, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,2,17]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"Howlader N Noone A Krapcho M et al. SEER cancer statistics review 1975-2012. Bethesda MD: National Cancer Institute 2018."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155212457964"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.04.004"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200412000-00003"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.03.013"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta9480"},{"key":"e_1_3_2_8_2","first-page":"164","article-title":"The evaluation and current concept of retinoblastoma therapy","volume":"67","author":"Reese A","year":"1963","unstructured":"Reese A, Ellsworth R. The evaluation and current concept of retinoblastoma therapy. Trans Am Acad Ophthalmol Otolaryngol 1963; 67: 164\u2013172.","journal-title":"Trans Am Acad Ophthalmol Otolaryngol"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23002"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.5858\/133.8.1199"},{"key":"e_1_3_2_11_2","first-page":"171","article-title":"Supraselective intra-arterial chemotherapy: evaluation of treatment-related complications in advanced retinoblastoma","volume":"5","author":"Vajzovic LM","year":"2011","unstructured":"Vajzovic LM, Murray TG, Aziz-Sultan MA, et\u00a0al. Supraselective intra-arterial chemotherapy: evaluation of treatment-related complications in advanced retinoblastoma. Clin Ophthalmol 2011; 5: 171\u2013176.","journal-title":"Clin Ophthalmol"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/IIO.0000000000000155"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.1.224"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(92)90038-K"},{"key":"e_1_3_2_15_2","first-page":"858","article-title":"Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay","volume":"78","author":"Inomata M","year":"1987","unstructured":"Inomata M, Kaneko A. Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay. Jpn J Cancer Res 1987; 78: 858\u2013868.","journal-title":"Jpn J Cancer Res"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","unstructured":"Yamane T Kaneko A Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol 2004; 9: 69\u201373.","DOI":"10.1007\/s10147-004-0392-6"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.150"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146582"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10633-012-9358-6"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2010.03.009"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.7"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.296"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-008-0636-5"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.5"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10633-008-9164-3"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.3171\/2011.1.JNS10466"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181cbda0f"},{"key":"e_1_3_2_28_2","unstructured":"AEMPS. Data sheet Melphalan Tillomed. Madrid Spain 2019 pp. 1\u201315."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.2324"},{"key":"e_1_3_2_30_2","unstructured":"Trissel LA. Handbook on injectable drugs. 15th ed. Bethesda MD: American Society of Health-System Pharmacists 2009 pp. 1005\u20131015."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1159\/000448718"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2011-301016"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2013.7666"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjopt.2013.06.003"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.03.028"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2011-301450"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-015-3149-1"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-303885"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2012.1983"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oftal.2014.09.015"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oftal.2018.04.010"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220904410","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220904410","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220904410","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:22:34Z","timestamp":1777688554000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220904410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,17]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1177\/1078155220904410"],"URL":"https:\/\/doi.org\/10.1177\/1078155220904410","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,17]]}}}